BeiGene Co.,Ltd

107 articles with BeiGene Co.,Ltd

• SpringWorks Therapeutics Announces Initiation of Phase 1b Clinical Trial of MEK Inhibitor PD-0325901 in Combination with BeiGene’s RAF Dimer Inhibitor Lifirafenib in Advanced or Refractory Solid Tumors

  5/6/2019

  SpringWorks Therapeutics, Inc. announced that the first patient has been dosed in a Phase 1b study to evaluate the combination of SpringWorks Therapeutics’ investigational MEK inhibitor, PD-0325901, and BeiGene, Ltd.’s investigational RAF dimer inhibitor, lifirafenib, in patients with advanced or refractory solid tumors.

• Ambrx and BeiGene Announce Global Research and Development Collaboration to Develop Next-Generation Biologics

  3/7/2019

  Ambrx Inc., a clinical-stage biopharmaceutical company focused on the development of innovative protein therapeutics and BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced a global research and development collaboration.

• BeiGene Receives U.S. FDA Breakthrough Therapy Designation for Zanubrutinib in Mantle Cell Lymphoma

  1/14/2019

   BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for its investigational Bruton’s tyrosine kinase (BTK) inhibitor, zanubrutinib,

• Zymeworks and BeiGene Announce License and Collaboration Agreement for Zymeworks’ HER2-Targeted Therapeutic Candidates, ZW25 and ZW49, in Asia-Pacific and Research and License Agreement for Zymeworks’ Azymetric™ and EFECT™ Platforms Globally

  11/27/2018

  BeiGene acquires exclusive development and commercial rights to Zymeworks’ bispecific candidates, ZW25 and ZW49, in Asia (excluding Japan), Australia, and New Zealand. The companies will collaborate on joint global development for selected indications.

• Zymeworks and BeiGene Announce License and Collaboration Agreement for Zymeworks’ HER2‑Targeted Therapeutic Candidates, ZW25 and ZW49, in Asia-Pacific and Research and License Agreement for Zymeworks’ Azymetric™ and EFECT™ platforms globally

  11/27/2018

  Zymeworks Inc. (NYSE/TSX: ZYME), and BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160),  today announced that the two companies have entered into a strategic collaboration for the clinical development and commercialization of Zymeworks’ investigational ZW25 and ZW49 HER2-targeted bispecific antibodies.

• BeiGene Announces Acceptance of its New Drug Application in China and Top-Line Pivotal Data for Zanubrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  10/24/2018

  BeiGene, Ltd. today announced the acceptance by the China National Medical Products Administration (NMPA) of a new drug application (NDA) for zanubrutinib, an investigational Bruton's tyrosine kinase (BTK) inhibitor

• 

  Innovent Biologics Plans Hong Kong IPO to Raise $423 Million, Despite Global Downturn

  10/15/2018

  China’s Innovent Biologics reportedly is continuing with its plans to raise $423 million in its Hong Kong IPO. If so, it would be the biggest biotech IPO out of Hong Kong this year.
• 

  Chinese Pharma Companies Continue to Shake Hands With Western Partners

  10/12/2018

  Brii Biosciences is one of many China-based companies that are heavily investing in U.S. biotech and pharmaceutical companies to support the development of programs that could come back to China for approval.

• MEI Pharma and BeiGene Announce Clinical Collaboration to Evaluate ME-401 in Combination with Zanubrutinib in Patients with B-Cell Malignancies

  10/11/2018

  MEI Pharma, Inc. and BeiGene, Ltd. today announced a clinical collaboration to evaluate the safety and efficacy of MEI's ME-401

• 

  Not Just Pocket Change: China's Hillhouse Capital's New Fund Has $10.6 Billion to Invest

  9/20/2018

  China’s Hillhouse Capital Group, an equity investment firm, has a new fund, Hillhouse Fund IV, with $10.6 billion ready to invest.

• BeiGene Selects GE Healthcare’s Off-the-Shelf Biologics Factory to Boost its Manufacturing Capacity for Cancer Drugs

  9/19/2018

  BeiGene to build late-stage clinical and commercial production capacity for cancer monoclonal antibodies with GE Healthcare’s KUBio, the prefabricated biopharma facility based on single-use technologies

• 

  R&D Cooperation Between China and Western Pharma Companies Up 70 Percent

  9/14/2018

  Without a doubt China has become one of the most important markets for pharma companies, given the vast patient population and the rising cancer rates. And it seems that western pharmaceutical companies are making greater inroads there.

• BeiGene and SpringWorks Therapeutics Enter into Global Clinical Collaboration to Evaluate Targeted Combination Therapy in Advanced Solid Tumors

  9/6/2018

  BeiGene’s RAF dimer inhibitor lifirafenib (BGB-283) and SpringWorks Therapeutics’ MEK inhibitor PD-0325901 to be studied in combination

• 

  China’s Beigene Teams up With Springworks to Target Advanced Solid Tumors

  9/6/2018

  SpringWorks Therapeutics and BeiGene, Ltd. have teamed up to develop therapeutics that will target advanced solid tumors that contain RAS mutations, as well as other MAPK aberrations.

• BeiGene Initiates New Phase 3 Trial of Anti-PD-1 Antibody Tislelizumab Combined with Chemotherapy as First-line Treatment for Patients with Advanced Squamous Non-Small Cell Lung Cancer in China

  8/9/2018

  BeiGene, Ltd. announced that the first patient was dosed in a Phase 3 clinical trial of tislelizumab, an investigational anti-PD-1 antibody, combined with chemotherapy, as a potential first-line treatment in China for patients with Stage IIIB or IV squamous non-small cell lung cancer (NSCLC).

• 

  BeiGene Sets Price for Hong Kong IPO, Rakes in Almost $1 Billion

  8/2/2018

  BeiGene, a biotech company based in Beijing, China and Cambridge, Massachusetts, announced it priced its initial public offering (IPO) on the Hong Kong stock exchange.
• 

  BeiGene Shows Off Strong Results from Checkpoint Inhibitor While Eying Potential Approval for BTK...

  7/23/2018

  BeiGene is starting off the week with a bang. Late Sunday the company announced positive preliminary topline results from its Phase II trial of tislelizumab, the company’s investigational checkpoint inhibitor for relapsed/refractory classical Hodgkin’s lymphoma (R/R cHL).  

• BeiGene Announces Commercial Availability of VIDAZA (Azacitidine for Injection) in China

  2/6/2018

  The drug is marketed in China by BeiGene under an exclusive license from Celgene Corporation.

• BeiGene Initiates Global Phase III Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Esophageal Squamous Cell Carcinoma

  1/31/2018

  Tislelizumab is also being studied in global Phase 3 trials in non-small cell lung cancer and hepatocellular carcinoma and two pivotal Phase 2 trials in China in relapsed/refractory classical Hodgkin lymphoma and urothelial cancer.

• 

  3 Overlooked Biopharmas Insiders are Snapping Up

  1/30/2018

  A look at three intriguing biotech stocks that are seeing big insider buying from top-ranked insiders right now.